Platinum-based chemotherapy rechallenge or enfortumab vedotin after maintenance avelumab or pembrolizumab for locally advanced or metastatic urothelial carcinoma.

ABSTRACT:

Background

In current clinical practice, the use of switch maintenance avelumab is recommended for patients with locally advanced and metastatic urothelial carcinoma who experience favorable responses to first-line chemotherapy.

Objective

We aimed to evaluate the potential advantages of platinum-based chemotherapy (Pl-CT) rechallenge after maintenance avelumab.

Methods

A retrospective analysis involving 383 patients treated with first-line Pl-CT between 2015 and 2023 was conducted. Subsequent treatment strategies included Pl-CT or enfortumab vedotin (EV) following maintenance avelumab or pembrolizumab, and their benefit was evaluated.

Results

Pl-CT rechallenge following maintenance avelumab did not show significant benefits, demonstrating lower response rates a

SUBMITTER: Nishimura N 

PROVIDER: S-EPMC11926830 | biostudies-literature | 2025 Jan-Mar

REPOSITORIES: biostudies-literature